Document is current
Any future updates will be listed below
-
Authors
Neczypor, Evan W.
Reisert, Hailey
Moore, Kelley
Zeldin, Elizabeth
Dubin, Robert A.
Battle, Lauren
He, Chuan
Hayashi, Masanori
Weiser, Daniel A.
Applebaum, Mark A.
-
Funding
Funding for this research was provided by:
Scholars in Oncology Research Award (R25CA240134)
New York Community Trust
National Pediatric Cancer Foundation
the University of Chicago Comprehensive Cancer (P30CA014599)
Institute for Translational Medicine (UL1TR000430)
- License Information
-
More Information
Article History
Received: 23 July 2025
Accepted: 2 February 2026
First Online: 11 February 2026
Competing interests
: C.H. is a scientific founder, a member of the scientific advisory board, and equity holder of Aferna Bio, Inc., and Ellis Bio Inc., a scientific cofounder and equity holder of Accent Therapeutics, Inc., and a member of the scientific advisory board of Rona Therapeutics and Elemental Biosciences, and declares no non-financial competing interests. The other authors declare no financial or non-financial competing interests.
